Synopsis
Synopsis
0
CEP/COS
0
EU WC
0
KDMF
0
VMF
0
FDF
0
Europe
0
Australia
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
Annual Reports
NA
1. Amciderm
2. Amcininide
3. Cl 34,699
4. Cyclocort
5. Cyclort
6. Penticort
7. Triamcinolone 16,17-cyclopentylidenedioxy-21-acetate
1. 51022-69-6
2. Cyclocort
3. Amcinonidum
4. Cl-34699
5. Triamcinolonacetatcyclopentanonid
6. Cl 34699
7. Visderm
8. Mls000028656
9. Mls001333715
10. Chebi:31199
11. 423w026ma9
12. Nsc-758620
13. Amcinonido
14. Smr000058920
15. [2-[(1s,2s,4r,8s,9s,11s,12r,13s)-12-fluoro-11-hydroxy-9,13-dimethyl-16-oxospiro[5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-diene-6,1'-cyclopentane]-8-yl]-2-oxoethyl] Acetate
16. [2-[(4r,8s,9s,11s,12r,13s)-12-fluoro-11-hydroxy-9,13-dimethyl-16-oxospiro[5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-diene-6,1'-cyclopentane]-8-yl]-2-oxoethyl] Acetate
17. Amcinonida
18. Amcinonidum [inn-latin]
19. Amcinonido [inn-spanish]
20. Cyclocort (tn)
21. Pregna-1,4-diene-3,20-dione, 21-(acetyloxy)-16,17-[cyclopentylidenebis(oxy)]-9-fluoro-11-hydroxy-, (11.beta.,16.alpha.)-
22. Amcinonide (jan/usp/inn)
23. Unii-423w026ma9
24. Ncgc00095071-01
25. (11?,16?)-21-(acetyloxy)-16,17-[cyclopentylidenebis(oxy)]-9-fluoro-11-hydroxypregna-1,4-diene-3,20-dione
26. Pregna-1,4-diene-3,20-dione, 21-(acetyloxy)-16,17-(cyclopentylidenebis(oxy))-9-fluoro-11-hydroxy-, (11.beta.,16.alpha.)-
27. Einecs 256-915-2
28. Amcinonide [usan:usp:inn:ban:jan]
29. Amcinonide [mi]
30. Amcinonide [inn]
31. Amcinonide [jan]
32. Opera_id_1472
33. Amcinonide [usan]
34. Amcinonide [vandf]
35. Amcinonide [mart.]
36. Schembl4720
37. 1,4-pregnadiene-2,20-dione-16,17-cyclopentylidenedioxy-9-fluoro-11,21-dihydroxy-21-acetate
38. Amcinonide [usp-rs]
39. Amcinonide [who-dd]
40. Dsstox_cid_25905
41. Dsstox_rid_81217
42. Dsstox_gsid_45905
43. 19alpha-fluor-11beta,21-dihydroxy-16alpha,17alpha-(tetramethylen)methylendioxy-1,4-pregnadien-3,20-dion 21-acetat
44. 9-fluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione Cyclic 16,17-acetal With Cyclopentanone, 21-acetate
45. Mls001146959
46. Mls002695893
47. Amcinonide, Analytical Standard
48. Gtpl7060
49. Amcinonide [orange Book]
50. Chembl1200732
51. Dtxsid6045905
52. Amcinonide [usp Monograph]
53. Hms2235k23
54. Hms3715d11
55. 9-fluoro-11.beta.,16.alpha.,17,21-tetrahydroxypregna-1,4-diene-3,20-dione Cyclic 16,17-acetal With Cyclopentanone, 21-acetate
56. Amy38534
57. Hy-b1197
58. Zinc3977777
59. Tox21_111411
60. S5671
61. Akos015961167
62. Amcinonide 100 Microg/ml In Methanol
63. Ccg-221135
64. Cs-4805
65. Db00288
66. Nsc 758620
67. Ncgc00021193-03
68. 16alpha,17alpha-(cyclopentane-1,1-diyldioxy)-9-fluoro-11beta-hydroxy-3,20-dioxopregna-1,4-dien-21-yl Acetate
69. Ac-13190
70. Pregna-1,4-diene-3,20-dione, 21-(acetyloxy)-16,17-(cyclopentylidenebis(oxy))-9-fluoro-11-hydroxy-, (11beta,16alpha)-
71. Cas-51022-69-6
72. D01387
73. Sr-01000003161
74. Q4742041
75. Sr-01000003161-2
76. Brd-k13960744-001-09-7
77. Amcinonide, United States Pharmacopeia (usp) Reference Standard
78. 5,6-dimethoxy-2-methyl-3-[2-(4-phenyl-1-piperazinyl)ethyl]-1h-indolehydrochloride
79. 2-((6a's,6b'r,7's,8a's,8b's,11a'r,12a's,12b's)-6b'-fluoro-7'-hydroxy-6a',8a'-dimethyl-4'-oxo-2',4',6a',6b',7',8',8a',8b',11a',12',12a',12b'-dodecahydro-1'h-spiro[cyclopentane-1,10'-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxole]-8b'-yl)-2-oxoethyl Acetate
80. 2-[(1's,2's,4'r,8's,9's,11's,12'r,13's)-12'-fluoro-11'-hydroxy-9',13'-dimethyl-16'-oxo-5',7'-dioxaspiro[cyclopentane-1,6'-pentacyclo[10.8.0.0^{2,9}.0^{4,8}.0^{13,18}]icosane]-14',17'-dien-8'-yl]-2-oxoethyl Acetate
Molecular Weight | 502.6 g/mol |
---|---|
Molecular Formula | C28H35FO7 |
XLogP3 | 3.6 |
Hydrogen Bond Donor Count | 1 |
Hydrogen Bond Acceptor Count | 8 |
Rotatable Bond Count | 4 |
Exact Mass | 502.23668161 g/mol |
Monoisotopic Mass | 502.23668161 g/mol |
Topological Polar Surface Area | 99.1 Ų |
Heavy Atom Count | 36 |
Formal Charge | 0 |
Complexity | 1090 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 8 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
1 of 2 | |
---|---|
Drug Name | Amcinonide |
PubMed Health | Amcinonide (Topical application route) |
Drug Classes | Adrenal Glucocorticoid, Corticosteroid, Strong |
Drug Label | The topical corticosteroids constitute a class of primarily synthetic steroids used as anti-inflammatory and antipruritic agents.Each gram of Amcinonide Ointment USP, 0.1% contains 1 mg of the active steroid amcinonide in a specially formulated base... |
Active Ingredient | Amcinonide |
Dosage Form | Lotion; Ointment; Cream |
Route | Topical |
Strength | 0.1% |
Market Status | Prescription |
Company | Fougera Pharms; Taro Pharm Inds |
2 of 2 | |
---|---|
Drug Name | Amcinonide |
PubMed Health | Amcinonide (Topical application route) |
Drug Classes | Adrenal Glucocorticoid, Corticosteroid, Strong |
Drug Label | The topical corticosteroids constitute a class of primarily synthetic steroids used as anti-inflammatory and antipruritic agents.Each gram of Amcinonide Ointment USP, 0.1% contains 1 mg of the active steroid amcinonide in a specially formulated base... |
Active Ingredient | Amcinonide |
Dosage Form | Lotion; Ointment; Cream |
Route | Topical |
Strength | 0.1% |
Market Status | Prescription |
Company | Fougera Pharms; Taro Pharm Inds |
For the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
FDA Label
Amcinonide is a topical corticosteroid. The topical corticosteroids constitute a class of primarily synthetic steroids used as anti-inflammatory and antipruritic agents. Amcinonide reduces or inhibits the actions of chemicals in the body that cause inflammation, redness, and swelling. The mechanism of anti-inflammatory activity of the topical corticosteroids is unclear. Various laboratory methods, including vasoconstrictor assays, are used to compare and predict potencies and/or clinical efficacies of the topical corticosteroids. There is some evidence to suggest that a recognizable correlation exists between vasoconstrictor potency and therapeutic efficacy in man. When in an ointment form, amcinonide also helps the skin maintain moisture.
Glucocorticoids
A group of CORTICOSTEROIDS that affect carbohydrate metabolism (GLUCONEOGENESIS, liver glycogen deposition, elevation of BLOOD SUGAR), inhibit ADRENOCORTICOTROPIC HORMONE secretion, and possess pronounced anti-inflammatory activity. They also play a role in fat and protein metabolism, maintenance of arterial blood pressure, alteration of the connective tissue response to injury, reduction in the number of circulating lymphocytes, and functioning of the central nervous system. (See all compounds classified as Glucocorticoids.)
D07AC11
S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355
D - Dermatologicals
D07 - Corticosteroids, dermatological preparations
D07A - Corticosteroids, plain
D07AC - Corticosteroids, potent (group iii)
D07AC11 - Amcinonide
Absorption
Topical corticosteroids can be absorbed from normal intact skin. Inflammation and/or other disease processes in the skin increase percutaneous absorption.
Route of Elimination
Corticosteroids are metabolized primarily in the liver and are then excreted by the kidneys. Some of the topical corticosteroids and their metabolites are also excreted into the bile.
Once absorbed through the skin, topical corticosteroids are handled through pharmacokinetic pathways similar to systemically administered corticosteroids. Corticosteroids are metabolized primarily in the liver and are then excreted by the kidneys.
The mechanism of the anti-inflammatory activity of the topical steroids, in general, is unclear. However, corticosteroids are thought to act by the induction of phospholipase A2 inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor, arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A2. Amcinonide has affinity for the glucocorticoid receptor. It has weak affinity for the progesterone receptor, and virtually no affinity for the mineralocorticoid, estrogen, or androgen receptors.
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
A Amcinonide manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Amcinonide, including repackagers and relabelers. The FDA regulates Amcinonide manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Amcinonide API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Amcinonide manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Amcinonide supplier is an individual or a company that provides Amcinonide active pharmaceutical ingredient (API) or Amcinonide finished formulations upon request. The Amcinonide suppliers may include Amcinonide API manufacturers, exporters, distributors and traders.
click here to find a list of Amcinonide suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Amcinonide DMF (Drug Master File) is a document detailing the whole manufacturing process of Amcinonide active pharmaceutical ingredient (API) in detail. Different forms of Amcinonide DMFs exist exist since differing nations have different regulations, such as Amcinonide USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Amcinonide DMF submitted to regulatory agencies in the US is known as a USDMF. Amcinonide USDMF includes data on Amcinonide's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Amcinonide USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Amcinonide suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Amcinonide Drug Master File in Japan (Amcinonide JDMF) empowers Amcinonide API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Amcinonide JDMF during the approval evaluation for pharmaceutical products. At the time of Amcinonide JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Amcinonide suppliers with JDMF on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Amcinonide as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Amcinonide API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Amcinonide as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Amcinonide and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Amcinonide NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Amcinonide suppliers with NDC on PharmaCompass.
Amcinonide Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Amcinonide GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Amcinonide GMP manufacturer or Amcinonide GMP API supplier for your needs.
A Amcinonide CoA (Certificate of Analysis) is a formal document that attests to Amcinonide's compliance with Amcinonide specifications and serves as a tool for batch-level quality control.
Amcinonide CoA mostly includes findings from lab analyses of a specific batch. For each Amcinonide CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Amcinonide may be tested according to a variety of international standards, such as European Pharmacopoeia (Amcinonide EP), Amcinonide JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Amcinonide USP).
LOOKING FOR A SUPPLIER?